Table of Contents
Published: July 13, 2026
Read Time: 5.9 Mins
Total Views: 29
Prevention has produced some of the highest returns in the history of health investment. Vaccination programs, lead abatement, road safety, and tobacco control each delivered societal benefits that dwarfed their cost, turning small upfront outlays into savings that recurred for decades across multiple sectors. The trouble is that the current structure of health finance directs money toward the large, recurring, downstream expense of treating disease rather than the small upfront investment that prevents it, and AI capital is following that same contour. Correcting it requires building a distinct investment case for each actor with the capacity to change the direction of the field.
Private funders and the adjacent markets they overlook
The most important shift will need to come from impact investors, family offices, and mission-aligned venture capital, who often assume that public health agencies have budgets too small to justify building AI tools for them. That assumption misses where the value lies. The capabilities public health needs, cleaning and connecting messy unstructured data, automating reporting and compliance, forecasting risk, managing logistics under uncertainty, and tailoring communication to many audiences, are demanded simultaneously by large health systems, social service operators, emergency response agencies, and the insurers and value-based care organizations whose business model genuinely rewards keeping people healthy. A funder willing to look past the narrowest definition of the customer will find adjacent markets that are real and can support a company serving both a public mission and a viable business. The reason capital has not already moved is that the public health buyer is fragmented across thousands of state, county, tribal, and local agencies, each with its own budget cycle and procurement rules, which is where government and philanthropy have to clear the path.
Technology companies and catastrophic risk
For technology firms, the case rests on market creation, infrastructure, catastrophic risk, and trust. A startup that builds the data, surveillance, and logistics tools public health needs can define a category in an underbuilt field with little competition. For the largest AI firms, the more compelling argument is self-interest rather than charity: a large-scale biological catastrophe is a tail risk to the global economy and to every major firm within it, and investing in the surveillance and response capability that would detect and contain such an event early is a rational hedge, the same logic that makes biosecurity worth the attention biosecurity experts are now paying it. These firms can also do what no one else can, by offering discounted or open access to frontier models for validated public health uses, donating compute, and seconding engineering talent to data modernization. There is a reputational dividend as well, because demonstrating that this technology can protect the public is among the more credible ways to answer the deep ambivalence it provokes.
Philanthropy and government
For philanthropy and government the case is more direct, since both exist to correct market failures. Philanthropy’s highest-leverage move is to fund what neither the market nor government will build: open, validated, inspectable AI tools, the reference datasets to evaluate them, and the independent testing that establishes what works. A philanthropically funded commons of public-interest tools answers the legitimate worry that agencies should not simply rent intelligence from vendors whose models and priorities they cannot inspect. Many observers expect a new golden age of philanthropy, on the order of thirty-seven billion dollars a year by one estimate, as wealth from the major AI companies becomes liquid, and that money could underwrite exactly this kind of shared foundation.
Government remains the primary funder and operator of public health, even as the case for funding it has grown politically harder since the pandemic and agencies lose money and people. Used well, AI can help maintain essential functions through that contraction, provided it extends the workforce rather than justifying its elimination. Government can also make the market more attractive by modernizing public data infrastructure, using its purchasing power to create a coherent market across jurisdictions, and setting the rules for data access and privacy that determine whether these tools earn public trust. In December 2025 the Department of Health and Human Services released its first AI strategy, and in March 2026 the Centers for Disease Control and Prevention published its own AI strategy for 2026 through 2030, even as the agency faces the scrutiny I have described in writing about how it has handled its own vaccine data. Both frameworks describe how government will use AI inside its own walls; both say far less about how the capital to build prevention-focused tools will be raised, who will build them, and how the smallest agencies will gain access.
From argument to mechanism
The arguments only matter if they translate into mechanisms. Philanthropy should treat a public health AI commons as core infrastructure and fund it through a pooled, multi-year vehicle with a single technical governance body, the way foundations have built shared scientific infrastructure before. Funders should also underwrite intermediary organizations that turn donated capital into operating ventures by defining the problems worth solving, recruiting founders, and providing the legal and operational scaffolding to launch quickly; Fedcap, which published the report behind this argument, has created Civic Health to do exactly that. The federal government should create a dedicated, milestone-driven funding stream modeled on ARPA-H, which funds high-risk health research that neither conventional programs nor industry will pursue and holds every project to measurable milestones. State and local governments should pool their purchasing through associations of health officials so that a company faces one coherent customer rather than thousands of incompatible ones, and should pay for demonstrated performance rather than software licenses alone. Private funders should adopt a deliberate thesis built around dual-use capability, with value-based care organizations as one of the most promising near-term markets, since they are among the few actors whose incentives already align with keeping people healthy. The same prevention logic that made tobacco control one of the best public health investments ever made applies here: pay a little now, in the right place, and save a great deal later.
